Background: Antiphospholipid syndrome is important as a cause of ischemic stroke, although clinical characteristics of the syndrome are not well documented. Methods: We analyzed differences in clinical characteristics between 40 antiphospholipid-antibody (aPL)-positive and 40 aPL-negative stroke patients. Results: Stroke patients with aPL were significantly younger and were more likely to be women in comparison with stroke patients without aPL. Valvular heart disease, neurological complications and hematological disorders were more frequent in the aPL-positive group. The mean value of thrombin-antithrombin III complex was significantly lower in the aPL-positive group. Cerebral infarctions in the carotid system were less and large-artery lesions more frequent in the aPL-positive patients. Conclusions: Stroke patients with aPL have clinical characteristics distinct from stroke patients without aPL.

Keywords:
Antiphospholipid syndrome, Cerebral infarction
1.
Euro-Phospholipid Project Group: Antiphospholipid syndrome. Arthritis Rheum 2002;46:1019–1027.
2.
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Hariss EN, Hughes GRV, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309–1311.
3.
The Committee of Japan Diabetic Society for Diagnostic Criteria of Diabetes Mellitus: Report of the Committee of Japan Diabetes Society on the classification and diagnostic criteria of diabetes mellitus (in Japanese). J Jpn Diab Soc 1999;42:385–404.
4.
Luong TH, Rand JH, Wu XX, Godbold JH, Gascon-Lema M, Tuhrim S: Seasonal distribution of antiphospholipid antibodies. Stroke 2001;32:1707–1711.
5.
Kushner M: Prospective study of anticardiolipin antibodies in stroke. Stroke 1990;21:295–298.
6.
Babazono Y: Clinical and hematological investigation of stroke patients with anticardiolipin antibodies (in Japanese). Jpn J Stroke 1991;14:272–278.
7.
The Antiphospholipid Antibodies in Stroke Study (APASS) Group: Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069–2073.
8.
Tuhrim S, Rand JH, Wu XX, Weinberger J, Horowitz DR, Goldman ME, Godbold JH: Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561–1565.
9.
The Antiphospholipid Antibodies in Stroke Study (APASS) Group: Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990;21:1268–1273.
10.
Levine SR, Deegan MJ, Futrell N, Welch KMA: Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181–1189.
11.
Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D: Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189–193.
12.
Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Tincani A, Khamashta MA, Balestrieri G, Tremoli E, Hess DC: Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237–240.
13.
Roubey RAS: Tissue factor pathway and the antiphospholipid syndrome. J Autoimmun 2000;15:217–220.
14.
Rand JH, Wu XX: Antibody-mediated disruption of annexin V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999;82:649–655.
15.
Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Soto AL, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M, Hughes GRV: Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. Am J Med 1994;96:3–9.
16.
Khamashta MA, Hughes GRV: Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 1995;7:389–394.
17.
Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93;1579–1587.
18.
Galve E, Riera JC, Pigrau Castillo GD, Soler JS, Miralda GP: Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1998;319:817–823.
19.
Atsumi T, Koike T: Cardiac valve disease and antiphospholipid syndrome. Intern Med 2000;39; 446–447.
20.
Mottram PM, Gelman JS: Mitral valve thrombus mimicking a primary tumor in the antiphospholipid syndrome. J Am Soc Echocardiogr 2002;15:746–748.
21.
Rademacher J, Sohngen D, Specker C, Janda I, Sitzer M: Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus? Acta Neurol Scand 1999;99:356–361.
22.
Chapman J, Rand JH, Brey RL, Levine SR, Blatt I, Khamashta MA, Shoenfeld Y: Non-stroke neurological syndromes associated with antiphospholipid antibodies: Evaluation of clinical and experimental studies. Lupus 2003;12:514–517.
23.
Tsutsumi Y, Mochizuki A, Maruyama K, Uchiyama S, Iwata M: Myelopathy in patients with antiphospholipid antibodies: Clinical features, pathogenesis, and review of literature (in Japanese). Rinshoshikeigaku 2004;44:655–660.
24.
Ozturk MA, Hazendaroglu IC, Turgut M, Goker H: Current debates in antiphospholipid syndrome: The acquired antibody-mediated thrombophilia. Thromb Haemost 2004;10:89–126.
25.
Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002;346:752–763.
26.
Ames PRJ, Tommashino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V: Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies – A crucial role for acquired free protein S deficiency. Thromb Haemost 1996;76:190–194.
27.
Uchiyama S, Yamazaki M, Hara Y, Iwata M: Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin Thromb Hemost 1997;23:535–541.
28.
Yamazaki M, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Aoshima K, Ikeda T: Plasma levels of lipoprotein (a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 1994;71:424–427.
29.
Ieko M: Antiphospholipid antibodies and thrombosis: The putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody (in Japanese). Jpn J Clin Pathol 2000;48:293–300.
30.
Naitoh S, Masahiro I, Takeda M, Atsumi T, Koike T: Evaluation of F1+2/TAT ratios in Japanese patients with antiphospholipid syndrome (in Japanese). Jpn J Clin Pathol 2000;48:540–546.
31.
Shibata S, Harpel PC, Gharavi A, Rand J, Howard F: Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532–2540.
32.
Best IM, Vansandani G, Rust G, Bumpers HL: Recurrent ischemia in a young man with the antiphospholipid syndrome. Am Surg 2002;68:598–602.
33.
Feldmann E, Levine SR: Cerebrovascular disease with antiphospholipid antibodies: Immune mechanisms, significance, and therapeutic options. Ann Neurol 1995;37:s114–s129.
34.
Kitagawa Y, Shinohara Y, Niwa K, Yoshitoshi M, Kametsu Y: Recurrence and prognosis in ischemic stroke patients with anticardiolipin antibody in Japan (in Japanese). Rinshoshinkeigaku 1994;34:799–804.
35.
Wang HC, Tu HC, Choi WM: Ischemic stroke in a teenage girl with primary antiphopholipid antibody syndrome. J Formos Med Assoc 2000;99:62–65.
36.
Schutt M, Wiedemann GJ, Seidel G, Neusch C, Vieregge P, Kluter H: Ischemic stroke due to transient thrombosis of the internal carotid artery in a patient with combined antiphospholipid syndrome and factor V Leiden. Am J Med 1999;107:527–528.
37.
Ames PRJ: Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: A unifying ‘membrane stress syndrome’ hypothesis. Lupus 1994;3:371–377.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.